We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+11.01%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.4B
AUM Growth
+$210M
Cap. Flow
+$20.2M
Cap. Flow %
0.59%
Top 10 Hldgs %
33.65%
Holding
105
New
22
Increased
13
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$107M
2
CRBU icon
Caribou Biosciences
CRBU
+$100M
3
CYTK icon
Cytokinetics
CYTK
+$43.4M
4
SOPH icon
SOPHiA GENETICS
SOPH
+$35.6M
5
AZN icon
AstraZeneca
AZN
+$33.6M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$166M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$68.5M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$43.5M
4
BIIB icon
Biogen
BIIB
+$37.8M
5
BAX icon
Baxter International
BAX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
76
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.65M 0.08%
+15,000
New +$2.41M
BYSI icon
77
BeyondSpring
BYSI
$40.1M
$2.55M 0.07%
+161,697
New +$2.91M
PRCT icon
78
Procept Biorobotics
PRCT
$1.1B
$2.48M 0.07%
+65,000
New +$2.49M
SPRY icon
79
ARS Pharmaceuticals
SPRY
$532M
$1.88M 0.06%
188,243
– –
ADAP
80
CALL
DELISTED
Adaptimmune Therapeutics
ADAP
$1.51M 0.04%
+291,800
New +$1.31M
ALNA
81
DELISTED
Allena Pharmaceuticals
ALNA
$256K 0.01%
284,285
– –
ACAD icon
82
CALL
Acadia Pharmaceuticals
ACAD
$4.93B
– –
-602,100
Closed -$14.7M
ACAD icon
83
Acadia Pharmaceuticals
ACAD
$4.93B
– –
-2,807,310
Closed -$68.5M
LONA
84
LeonaBio Inc
LONA
$72.1M
– –
-67,825
Closed -$6.95M
BAX icon
85
Baxter International
BAX
$14.1B
– –
-458,667
Closed -$36.9M
BCRX icon
86
BioCryst Pharmaceuticals
BCRX
$2.31B
– –
-708,927
Closed -$11.2M
CNC icon
87
CALL
Centene
CNC
$33.1B
– –
-225,000
Closed -$16.4M
CYTK icon
88
CALL
Cytokinetics
CYTK
$10.7B
– –
-268,600
Closed -$5.32M
DOCS icon
89
Doximity
DOCS
$3.94B
– –
-30,000
Closed -$1.75M
INNV icon
90
InnovAge Holding
INNV
$1.51B
– –
-429,699
Closed -$9.16M
LH icon
91
Labcorp
LH
$25.4B
– –
-74,077
Closed -$17.6M
MRNA icon
92
PUT
Moderna
MRNA
$22.5B
– –
-141,000
Closed -$33.1M
NTLA icon
93
CALL
Intellia Therapeutics
NTLA
$1.53B
– –
-85,000
Closed -$13.8M
STTK icon
94
Shattuck Labs
STTK
$704M
– –
-326,813
Closed -$9.47M
OSH
95
DELISTED
Oak Street Health, Inc.
OSH
– –
-67,250
Closed -$3.94M
MYOV
96
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-1,912,188
Closed -$43.5M
ONEM
97
DELISTED
1Life Healthcare
ONEM
– –
-171,689
Closed -$5.68M
ARNA
98
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-345,523
Closed -$23.6M
ALXN
99
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-901,441
Closed -$166M
CNST
100
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-469,664
Closed -$15.9M
1 2 3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

PFM Health Sciences's Q3 2021 Portfolio in Review

As of Q3 2021, PFM Health Sciences held 105 positions worth $3.4B, up 6.6% from $3.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences's Q3 2021 filing shows 22 new, 13 increased, 16 reduced and 20 closed positions. Its largest new stake was Erasca: 5,191,405 shares worth $98.2M. The largest sale was Alexion Pharmaceuticals, an estimated $166M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 92% a quarter earlier, followed by Financials.

  • PFM Health Sciences's largest Q3 2021 buy was Erasca: 5,191,405 shares worth $98.2M.
  • PFM Health Sciences added most to Cytokinetics in Q3 2021, an estimated $43.4M increase.
  • PFM Health Sciences's biggest Q3 2021 reduction was Biogen, cutting an estimated $37.8M.
  • PFM Health Sciences fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $166M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $3.4B portfolio in Q3 2021.
  • PFM Health Sciences opened 22 new positions and closed 20 in Q3 2021.
  • PFM Health Sciences's portfolio value rose 6.6% quarter-over-quarter to $3.4B.

Based on PFM Health Sciences's 13F filing for Q3 2021, filed 15 Nov 2021.